Lung | Maryland Oncology Hematology Lung – Maryland Oncology Hematology

Trial ID ESR 22-21698 (EIMPRIS)

NCT05438498
clinicaltrials.gov ID
Phase II/III

Trial ID 20412

NCT04819100
clinicaltrials.gov ID
USOR ID: 20412 Phase III
A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432)

Trial ID 21318

NCT05170204
clinicaltrials.gov ID
USOR ID: 21318 Phase III
A PHASE I-III, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS, WITH LOCALLY ADVANCED, UNRESECTABLE, STAGE III NON-SMALL CELL LUNG CANCER 

Trial ID 21239

NCT04988295
clinicaltrials.gov ID
USOR ID: 21239 Phase III
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure

Trial ID

NCT03520686
clinicaltrials.gov ID
Phase III

Trial ID 21541

NCT05215340
clinicaltrials.gov ID
USOR ID: 21541 Phase III
Tropion-Lung08: A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations

Trial ID 21320

NCT04486833
clinicaltrials.gov ID
USOR ID: 21320 Phase I/II
A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination with Osimertinib in Patients with Advanced, EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer who have Progressed after Treatment with Osimertinib

Trial ID 20422

USOR ID: 20422 Phase N/A
KRAS DetECT: KRAS mutation Detection to Evaluate Eligibility for Clinical Trials

Trial ID

NCT03175224
clinicaltrials.gov ID
Phase I/II

Trial ID 20266

NCT04485013
clinicaltrials.gov ID
USOR ID: 20266 Phase Ib
A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, as Monotherapy and in Combination with Pembrolizumab or Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies

Trial ID 19151

NCT03785249
clinicaltrials.gov ID
USOR ID: 19151 Phase II
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Trial ID 20270

NCT04613596
clinicaltrials.gov ID
USOR ID: 20270 Phase II
A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Trial ID 21219

NCT05054725
clinicaltrials.gov ID
USOR ID: 21219 Phase II
RMC-4630-03: A Phase 2, Open-Label, Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Trial ID 19151

NCT03785249
clinicaltrials.gov ID
USOR ID: 19151 Phase II
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Trial ID 20331

NCT04620330
clinicaltrials.gov ID
USOR ID: 20331 Phase II
A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) Non-Small Cell Lung Cancer

Trial ID 20423

NCT04622007
clinicaltrials.gov ID
USOR ID: 20423 Phase II
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy

Trial ID

NCT04589845
clinicaltrials.gov ID
Phase II

Trial ID 20249

NCT04538664
clinicaltrials.gov ID
USOR ID: 20249 Phase III
A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cance

Trial ID 20289

NCT04254107
clinicaltrials.gov ID
USOR ID: 20289 Phase I
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology